It might finally be time to short this bad boy. Stock has been on the run of all runs, and today possibly caps an unbelievable buying crescendo as it truly feels as though sentiment may have peaked.
Piecing into this seems like the move because it's going to be hard to tell when it's peaked precisely.
The only way to short this would be with a defined risk put spread. I'm looking for entries in the SEP 250->220 verts
Comment
⋅
took some of the position off this morning for a 60% gain
Comment
⋅
took more off for a 187% profit. down to about 60% of the position remaining
Comment
⋅
took more off for a 310% profit. about 35% of position remaining.
On a very tight tech analysis time window, sure. There has been a short lived market correction but whoever followed this advise based on a mid or long-term strategy (put options for this week, imagine) , they are surely not happy.
My statement stands and I bought more, this correction was a good and obvious thing but I wouldn’t call it a success on the bearish arguments against Moderna. It is above 400$ as we speak..
So.. a disruptive, life-changing (and saving) genetic technology with real potential to treat cancer, rare genetic disorders… A company with 24 vaccine candidates, including vaccine candidates for seasonal flu, HIV, etc.. Overbought? Yes.
But the fundamentals are rock solid and new variants and billions yet to be vaccinated make Moderna a clear buy after maybe a light market correction.. covid is going nowhere and their cash flow will allow for growth once manufacturing can keep up with demand.
IMO as of right now none of this technical analysis can be applied and whoever shorts this stock based on indicators will be crushed. Time will tell..
PropNotes
⋅
@fourthaspersion, nothing in your comment is incorrect but I read it as peak sentiment. Do you think it should be worth 70% of PFE? MRNA has one product and PFE has dozens. the valuation is insane and the technicals are parabolic.
Tazatron
⋅
@DiscordiaResearch, As big as PFE is it will soon be obsolete technology, MRNA is a new platform, a leap through technology on how Vaccines are being manufactured and administered using AI and ML. While I agree the RSI is way out there at all time highs and the stock certainly over extended, I have to disagree with you on valuation, we are undervalued trading at 16 FPE with an industry average of 30, look for $750-800 over the next 3-6 months, with 2-3X in 2022.
PropNotes
⋅
@Tazatron, SDGR is the actual AI ML play within healthcare AFAIK, again I agree MRNA is operationally fantastic but the valuation up here is aggressive to say the least, especially given how long it will take for the other candidates will bear fruit as well as the increasing competition in the space. I think we are saying the same things. I bot the SEP contracts so im not a long term bear on the name